CompuGroup Medical SE & Co. KGaA Stock
Pros and Cons of CompuGroup Medical SE & Co. KGaA in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of CompuGroup, a company operating in the US, provide a mixed picture at first glance. Although the company has shown a steady increase in total assets, liabilities, and revenues over the past years, there are also some areas for improvement that merit further analysis.
Consistent Growth in Total Assets and Total Revenue: CompuGroup's total assets have been steadily growing from €1.57 billion in 2020 to €1.79 billion in 2021 and further to €1.94 billion in 2022. A similar upward trend can be observed in the company's total revenues, which increased from €837 million in 2020 to €1.03 billion in 2021 and €1.13 billion in 2022. This reflects a robust and healthy growth rate for the company.
Stable Operating Income and EBITDA: CompuGroup has managed to maintain stable operating income figures over the past few years, with €121 million in 2020, €107 million in 2021, and €107 million in 2022. The EBITDA figures have also shown resilience, improving from €191 million in 2020 to €214 million in 2021 and €228 million in 2022.